March 30, 2024

Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia – Yahoo Finance

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that Bentrio™ has been approved by the Ministry of Health of Indonesia and is, therefore, cleared for commercialization in that country.

The product will be commercialized through the local affiliate of Wellesta Holdings Pte Ltd, Singapore (“Wellesta”). Indonesia has a population of approxim…….

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that Bentrio™ has been approved by the Ministry of Health of Indonesia and is, therefore, cleared for commercialization in that country.

The product will be commercialized through the local affiliate of Wellesta Holdings Pte Ltd, Singapore (“Wellesta”). Indonesia has a population of approximately 277 million people, the world’s fourth largest. Under a previously announced marketing and distribution agreement between the two companies, Wellesta will commercialize and distribute Bentrio in India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Vietnam and Marocco (the “Territory”). Within the Territory, Bentrio previously already received clearance in Singapore, Malaysia and the Philippines.

“Indonesia is the latest country joining the growing list of countries where Bentrio is approved,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “Together with our partner Wellesta we will be very pleased to make our innovative nasal spray available shortly for protection against airborne allergens and viruses.”

About Bentrio

Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. For more info, visit:

https://altamiratherapeutics.com/our-products/bentrio.

Bentrio is being distributed in selected European countries and is expected to become available through distributors in further countries in Europe, Asia and MENA. In the US, Altamira submitted a 510(k) application of Bentrio in the treatment of allergic rhinitis, which is currently under review by the FDA.

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq:CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/.

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities …….

Source: https://finance.yahoo.com/news/altamira-therapeutics-announces-marketing-approval-124700790.html